ATE505473T1 - Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c - Google Patents

Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c

Info

Publication number
ATE505473T1
ATE505473T1 AT08851253T AT08851253T ATE505473T1 AT E505473 T1 ATE505473 T1 AT E505473T1 AT 08851253 T AT08851253 T AT 08851253T AT 08851253 T AT08851253 T AT 08851253T AT E505473 T1 ATE505473 T1 AT E505473T1
Authority
AT
Austria
Prior art keywords
hepatitis
cyclopropyl
condensed
treatment
indolobenzazepine
Prior art date
Application number
AT08851253T
Other languages
English (en)
Inventor
John A Bender
Zhong Yang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE505473T1 publication Critical patent/ATE505473T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08851253T 2007-11-21 2008-11-17 Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c ATE505473T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98947207P 2007-11-21 2007-11-21
PCT/US2008/083729 WO2009067392A1 (en) 2007-11-21 2008-11-17 Cyclopropyl fused indolobenzazepine derivatives for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
ATE505473T1 true ATE505473T1 (de) 2011-04-15

Family

ID=40297935

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08851253T ATE505473T1 (de) 2007-11-21 2008-11-17 Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c

Country Status (8)

Country Link
US (1) US8124601B2 (de)
EP (1) EP2215095B1 (de)
JP (1) JP2011504178A (de)
CN (1) CN101918412B (de)
AT (1) ATE505473T1 (de)
DE (1) DE602008006257D1 (de)
ES (1) ES2362560T3 (de)
WO (1) WO2009067392A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
JP2011515486A (ja) 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の治療用化合物
CN102046630A (zh) 2008-03-27 2011-05-04 百时美施贵宝公司 吡咯烷稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
JP2011515496A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
US9556204B2 (en) * 2012-07-18 2017-01-31 Bristol-Myers Squibb Company Methods and intermediates for the preparation of (4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo [3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-A]indole-9-carboxamide
US9616905B2 (en) 2015-06-02 2017-04-11 Westinghouse Air Brake Technologies Corporation Train navigation system and method
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
AU7121198A (en) * 1997-04-18 1998-11-13 California Institute Of Technology Multifunctional polymeric tissue coatings
US6696073B2 (en) * 1999-02-23 2004-02-24 Osteotech, Inc. Shaped load-bearing osteoimplant and methods of making same
US6855160B1 (en) * 1999-08-04 2005-02-15 C. R. Bard, Inc. Implant and agent delivery device
US20040009228A1 (en) * 1999-11-30 2004-01-15 Pertti Tormala Bioabsorbable drug delivery system for local treatment and prevention of infections
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
CA2423431A1 (en) * 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
JP2004516262A (ja) * 2000-12-21 2004-06-03 ネクター セラピューティクス 親水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法
DE10114247A1 (de) * 2001-03-22 2002-10-10 Heraeus Kulzer Gmbh & Co Kg Antibiotikum-/Antibiotika-Polymer-Kombination
WO2003000156A1 (en) * 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US6648849B2 (en) * 2001-06-27 2003-11-18 Ethicon, Inc. Medicinal implant and device and method for loading and delivering implants containing drugs and cells
US7314636B2 (en) * 2001-06-29 2008-01-01 Medgraft Microtech, Inc. Biodegradable injectable implants containing glycolic acid
US7056338B2 (en) * 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
GB2404865B (en) * 2001-09-11 2005-09-28 Caretek Medical Ltd Novel drug delivery technology
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
IN2014DN10834A (de) * 2001-09-17 2015-09-04 Psivida Inc
US6827737B2 (en) * 2001-09-25 2004-12-07 Scimed Life Systems, Inc. EPTFE covering for endovascular prostheses and method of manufacture
US6926903B2 (en) * 2001-12-04 2005-08-09 Inion Ltd. Resorbable polymer composition, implant and method of making implant
CA2497195C (en) * 2001-12-14 2014-07-08 The University Of Wyoming Methods and compositions for controlled release of drugs
WO2003061634A1 (en) * 2002-01-24 2003-07-31 Smart Drug Systems Inc Sustained release pharmaceutical composition
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
TW200400963A (en) * 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
US7049348B2 (en) * 2002-07-06 2006-05-23 Kensey Nash Corporation Resorbable structure for treating and healing of tissue defects
US20040006146A1 (en) * 2002-07-06 2004-01-08 Evans Douglas G. Resorbable structure for treating and healing of tissue defects
US6916483B2 (en) * 2002-07-22 2005-07-12 Biodynamics, Llc Bioabsorbable plugs containing drugs
JP2005537909A (ja) * 2002-07-31 2005-12-15 マクロポー バイオサージェリー インコーポレイテッド インプラントと周囲の組織との間の癒着を防ぐための装置及び方法
EP1530491A1 (de) * 2002-08-13 2005-05-18 Medtronic, Inc. Vorrichtungen zur verabreichung von wirkstoffen, medizinische vorrichtungen, und verfahren
US7951392B2 (en) * 2002-08-16 2011-05-31 Boston Scientific Scimed, Inc. Microarray drug delivery coatings
US20050070989A1 (en) * 2002-11-13 2005-03-31 Whye-Kei Lye Medical devices having porous layers and methods for making the same
US7758881B2 (en) * 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20050079199A1 (en) * 2003-02-18 2005-04-14 Medtronic, Inc. Porous coatings for drug release from medical devices
US20080051866A1 (en) * 2003-02-26 2008-02-28 Chao Chin Chen Drug delivery devices and methods
US20060083767A1 (en) * 2003-02-27 2006-04-20 Kai Deusch Surgical prosthesis having biodegradable and nonbiodegradable regions
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
CA2518883A1 (en) * 2003-03-14 2004-09-23 Debio Recherche Pharmaceutique S.A. Subcutaneous delivery system, process for the preparation of the same and use of the same for the treatment of cholinergic deficient disorders
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US8007823B2 (en) * 2003-04-03 2011-08-30 Corporation De L'ecole Polytechnique De Montreal Microporous articles comprising biodegradable medical polymers, method of preparation thereof and method of use thereof
US20060105018A1 (en) * 2004-11-17 2006-05-18 Epstein Samuel J Therapeutic driving layer for a medical device
AU2004237774B2 (en) * 2003-05-02 2009-09-10 Surmodics, Inc. Implantable controlled release bioactive agent delivery device
AU2004238026A1 (en) * 2003-05-16 2004-11-25 Cinvention Ag Medical implants comprising biocompatible coatings
ZA200509063B (en) * 2003-05-30 2007-03-28 Titan Pharmaceuticals Inc Impiantable polymeric device for sustained release of nalmefene
AU2003233838A1 (en) * 2003-06-04 2005-01-04 Inion Ltd Biodegradable implant and method for manufacturing one
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
CA2530120A1 (en) * 2003-06-26 2005-01-06 Mediolanum Pharmaceuticals Ltd. Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
FI20045223A7 (fi) * 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US9114199B2 (en) * 2003-07-31 2015-08-25 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US7914805B2 (en) * 2003-07-31 2011-03-29 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agent
US8870814B2 (en) * 2003-07-31 2014-10-28 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing silicone copolymer for controlled delivery of therapeutic agent
US7357940B2 (en) * 2003-07-31 2008-04-15 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing graft copolymer for controlled delivery of therapeutic agents
US20050037047A1 (en) * 2003-08-11 2005-02-17 Young-Ho Song Medical devices comprising spray dried microparticles
US8529625B2 (en) * 2003-08-22 2013-09-10 Smith & Nephew, Inc. Tissue repair and replacement
NZ545521A (en) * 2003-09-23 2010-02-26 Orthocon Inc Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
WO2005039668A2 (en) * 2003-10-21 2005-05-06 Boiarski Anthony A Implantable drug delivery device for sustained release of therapeutic agent
US7435256B2 (en) * 2003-11-06 2008-10-14 Boston Scientific Scimed, Inc. Method and apparatus for controlled delivery of active substance
EP2286791B1 (de) * 2003-12-30 2014-03-26 Durect Corporation Polymereimplantate, welche vorzugsweise ein Gemisch von PEG und PLG enthalten, für kontrollierte Freisetzung von Wirkstoffen
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
WO2006002399A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable implantable medical devices, methods and systems
DE602005017177D1 (de) * 2004-07-05 2009-11-26 Ziscoat N V Biokompatible beschichtung von medizinischen vorrichtungen mit molekularsieben
ATE372772T1 (de) * 2004-07-13 2007-09-15 Schering Oy Retardiertes freigabesystem mit kontrollierter initialabgabe
US7713539B2 (en) * 2004-07-19 2010-05-11 Boston Scientific Scimed, Inc. Medical devices containing radiation resistant block copolymer
US7771740B2 (en) * 2004-07-19 2010-08-10 Boston Scientific Scimed, Inc. Medical devices containing copolymers with graft copolymer endblocks for drug delivery
EP1781264B1 (de) * 2004-08-04 2013-07-24 Evonik Corporation Verfahren zur herstellung von abgabevorrichtungen und damit erhaltene vorrichtungen
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CN101018512B (zh) * 2004-08-13 2011-05-18 马斯特生物外科股份公司 具有可生物降解区和不可生物降解区的外科手术假体
US20060039946A1 (en) * 2004-08-20 2006-02-23 Medtronic Inc. Drug eluting medical device
US20060051390A1 (en) * 2004-09-03 2006-03-09 Schwarz Marlene C Medical devices having self-forming rate-controlling barrier for drug release
CN101890167B (zh) * 2004-10-01 2017-03-01 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
EP1807397A2 (de) 2004-10-26 2007-07-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Tetrazyklische indolderivate als antivirale wirkstoffe
US20070009564A1 (en) * 2005-06-22 2007-01-11 Mcclain James B Drug/polymer composite materials and methods of making the same
WO2007001624A2 (en) * 2005-06-28 2007-01-04 Microchips, Inc. Medical and dental implant devices for controlled drug delivery
US8722074B2 (en) * 2005-07-19 2014-05-13 Boston Scientific Scimed, Inc. Medical devices containing radiation resistant polymers
US20070048350A1 (en) * 2005-08-31 2007-03-01 Robert Falotico Antithrombotic coating for drug eluting medical devices
US20070053952A1 (en) * 2005-09-07 2007-03-08 Medtronic Vascular, Inc. Nitric oxide-releasing polymers derived from modified polymers
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
JP5178520B2 (ja) * 2005-09-22 2013-04-10 メディバス エルエルシー 固体ポリマー送達組成物およびその使用法
US8784860B2 (en) * 2005-10-27 2014-07-22 Cordis Corporation Local administration of a combination of rapamycin and cilostazol for the treatment of vascular disease
US20070116736A1 (en) * 2005-11-23 2007-05-24 Argentieri Dennis C Local vascular delivery of PI3 kinase inhibitors alone or in combination with sirolimus to prevent restinosis following vascular injury
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN105327393A (zh) * 2006-06-22 2016-02-17 南佛罗里达大学 胶原支架、具有其的医用植入物以及使用方法
US7638344B2 (en) * 2006-06-28 2009-12-29 Surmodics, Inc. Active agent eluting matrices with particulates
US7731987B2 (en) * 2006-07-13 2010-06-08 Advanced Cardiovascular Systems, Inc. Implantable medical device comprising a pro-healing poly(ester-amide)
US8506984B2 (en) * 2006-07-26 2013-08-13 Cordis Corporation Therapeutic agent elution control process
US20080057103A1 (en) * 2006-08-21 2008-03-06 Wouter Roorda Methods of using medical devices for controlled drug release
US20080075753A1 (en) * 2006-09-25 2008-03-27 Chappa Ralph A Multi-layered coatings and methods for controlling elution of active agents
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders

Also Published As

Publication number Publication date
DE602008006257D1 (de) 2011-05-26
JP2011504178A (ja) 2011-02-03
US8124601B2 (en) 2012-02-28
EP2215095B1 (de) 2011-04-13
WO2009067392A1 (en) 2009-05-28
CN101918412B (zh) 2013-06-05
ES2362560T3 (es) 2011-07-07
EP2215095A1 (de) 2010-08-11
US20090130056A1 (en) 2009-05-21
CN101918412A (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
ATE483712T1 (de) Hcv-ns5b-inhibitoren
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
EA200900298A1 (ru) Ингибиторы вируса гепатита с
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
EA201001273A1 (ru) Ингибиторы вируса гепатита с
EA201101082A1 (ru) Ингибиторы вируса гепатита с
EA201270656A1 (ru) Ингибиторы вируса гепатита с
EA201171208A1 (ru) Ингибиторы вируса гепатита с
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
EA201100390A1 (ru) Соединения для лечения гепатита с
DK2250163T3 (da) Hepatitis C-virusinhibitorer
EA200900297A1 (ru) Ингибиторы вируса гепатита с
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA200870164A1 (ru) Лечение вирусного гепатита
EA201001748A1 (ru) Соединения, используемые для лечения гепатита с
EA201270798A1 (ru) Соединения для лечения гепатита с
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties